Previous work involving bradykinin analogs in glioma models demonstrated a peak of increased drug delivery after 15 minutes of RMP-7 infusion (40), a size limitation for access to the brain of 1 kDa–sized molecules (41) and dose-limiting side-effects. Here, KNG1 is linked to glioma.